Type 1 Diabetes Patients With Different Residual Beta-Cell Function but Similar Age, HBA1c, and Cardiorespiratory Fitness Have Differing Exercise-Induced Angiogenic Cell Mobilisation

Guy S. Taylor1*, Andy Shaw1, Jadine H. Scragg1,2, Kieran Smith1, Matthew D. Campbell3,4, Timothy J. McDonald5,6, James A. Shaw7,8, Mark D. Ross9 and Daniel J. West1*

Background: Many individuals with type 1 diabetes retain residual beta-cell function. Sustained endogenous insulin and C-peptide secretion is associated with reduced diabetes related complications, but underlying mechanisms remain unclear. Lower circulating numbers of endothelial and hematopoietic progenitor cells (EPCs and HPCs), and the inability to increase the count of these cells in response to exercise, are also associated with increased diabetes complications and cardiovascular disease. It is unknown whether residual beta-cell function influences HPCs and EPCs. Thus, this study examined the influence of residual beta-cell function in type 1 diabetes upon exercise-induced changes in haematopoietic (HPCs) and endothelial progenitor cells (EPCs).

Methods: Participants with undetectable stimulated C-peptide (n=11; Cpepund), 10 high C-peptide (Cpephigh; >200 pmol/L), and 11 non-diabetes controls took part in this observational exercise study, completing 45 minutes of intensive walking at 60% $\dot{V}O_2$peak. Clinically significant HPCs (CD34*+) and EPCs (CD34*VEGFR2*) phenotypes for predicting future adverse cardiovascular outcomes, and subsequent cell surface expression of chemokine receptor 4 (CXCR4) and 7 (CXCR7), were enumerated at rest and immediately post-exercise by flow cytometry.

Results: Exercise increased HPCs and EPCs phenotypes similarly in the Cpephigh and control groups (+34-121% across phenotypes, p<0.04); but Cpepund group did not
1 INTRODUCTION

Residual beta-cell function can persist in individuals with established type 1 diabetes, with between 35% to 80% of participants estimated to have detectable function at >5 years post diagnosis (1, 2). Sustained endogenous insulin and C-peptide secretion appears protective against complications in type 1 diabetes (3–7), however the underlying mechanisms are unclear. It is likely that the improved glycaemic control that is associated with residual beta-cell function (5, 7–10) results in reduced vascular damage, with hyperglycaemia acknowledged as the principal cause of microvascular complications (11). However, significant reductions in HbA1c and time spent in hyperglycaemia only occur at high beta-cell function (C-peptide ~200 pmol/L) (4, 9, 12), while even very low levels of beta-cell function may offer protection against diabetes-related complications (C-peptide >10 pmol/L) (5, 7, 13). It is unclear how beta-cell function may protect against complications independently of reducing hyperglycaemic induced damage.

There is a plethora of evidence that haematopoietic stem/progenitor cells (HPC), and endothelial progenitor cells (EPCs) have the potential to stimulate vascular repair (14–16). Identifiable by flow cytometry, HPCs are mononuclear cells in the peripheral blood expressing markers of haematopoiesis, such as CD34 (17), while EPCs have additional endothelial markers such as VEGFR2 (18). Compared to matched healthy controls, individuals with type 1 diabetes have reduced circulating counts of both HPCs and EPCs (19–24), with lower resting counts associated with increased occurrence of diabetes complications and cardiovascular disease (CVD) (19, 20, 25, 26). Recently, it has been suggested that exercise-induced mobilisation of angiogenic cells, comparable to the numbers found in matched non-diabetes controls (26). Therefore, the aim of this study was to explore whether residual beta-cell function in type 1 diabetes influences HPC and EPC mobilisation in response to exercise, and to compare against non-diabetes controls.

2 MATERIALS AND METHODS

2.1 Study Design

This analysis in individuals with type 1 diabetes ≥3 years’ duration, was a pre-specified secondary outcome of an observational study comparing exercise-induced changes with non-diabetes controls (31) (registry:ISRCTN63739203). Recruitment, consent, research design; including blood glucose management, and ethical approval has been described in detail elsewhere (31). Briefly, participants with type 1 diabetes had a confirmed clinical diagnosis; a diabetes duration ≥ 3 years; age 18–65 years; HbA1c < 86 mmol/mol (10.0%); and absence of diabetes-related complications, including any history of neuropathy or kidney issues, apart from non-proliferating retinopathy. For the non-diabetes participants, eligibility criteria comprised being aged between 18 and 65 years, non-smoker, and free from any history of chronic diseases. Participants provided written informed consent and the study was approved by the NHS HRA North East Tyne & Wear South Research Ethics and Newcastle University Ethics Committees (code:16/NE/0192).

All participants attended the Newcastle NIHR Clinical Research Facility (CRF) to determine peak oxygen uptake (\(VO_{2\text{peak}}\)) and to complete the main trial. Participants with type 1 diabetes also completed a mixed-meal tolerance test visit. Recruitment and data collection ran from October 2016 to September 2019.

2.2 Mixed-Meal Tolerance Test

Participants attended the CRF after an overnight fast, as previously described (10). Briefly, participants were given 240 mL Fortisip (Nutricia, Trowbridge, U.K.) (360 kcal, 14.4 g...
protein, 13.92 g fat, and 44.16 g carbohydrate) to drink within 2 min (34). Blood samples were drawn at baseline and every 30 min after consumption, up to 180 minute. Peak serum C-peptide was used to stratify participants. Eleven with undetectable C-peptide (Cpepund <3 pmol/L) and 10 with high residual C-peptide (Cpephigh >200 pmol/L) were included in the current analysis.

2.3 \( \dot{V}O_{2\text{peak}} \) Trial
Participants attended the CRF exercise lab to determine \( \dot{V}O_{2\text{peak}} \) and screen for any cardiac abnormalities. Participants underwent a modified 12-lead resting and exercising electrocardiogram as well as completing a maximal graded walking treadmill (Valiant 2 CPET; Lode, Groningen, the Netherlands) Bruce protocol test (35) to determine \( \dot{V}O_{2\text{peak}} \).

2.4 Main Trial
Participants attended the CRF exercise lab after an overnight fast. Participants with type 1 diabetes maintained their normal basal insulin regimen. If they experienced a hypoglycemic event overnight prior to the study visit, the visit was cancelled and reorganised. If upon waking blood glucose was > 10 mmol/L, they were instructed to have a small corrective bolus of rapid-acting insulin (≤ 2 units).

Cannulation was performed into an antecubital vein, and after discarding the initial 4ml drawn to avoid contamination of mature endothelial cells disturbed from the punctured vein, resting blood samples were drawn. A 10 mL EDTA vacutainer (Becton, Dickinson and Company, New York, USA) was collected at rest and, immediately post-exercise for flow cytometry enumeration. An additional 4 mL EDTA Vacutainer was for analysis of HbA1c at the Newcastle Clinical Laboratory. Capillary blood was collected at all-time points and analysed by a HemoControl analyser (EKF, Cardiff, UK) to determine haematocrit and haemoglobin concentration.

Participants consumed a 30 g carbohydrate snack (Belvita, Mondeléz International, USA) immediately after baseline blood draws and remained seated for 20 min. The exercise bout comprised of incline walking (9.0±4.6% at 4.9±1.0kph) for 45 minutes at 60% \( \dot{V}O_{2\text{peak}} \) with respiratory parameters (Metalyzer\textsuperscript{®} 3B-R3 CPET, Cortex, Leipzig, Germany) recorded throughout. If \( \dot{V}O_{2} \) was >10% different than target \( \dot{V}O_{2} \) at 10 and 30 min into the exercise, the gradient was adjusted. Participants with type 1 diabetes had a target capillary blood glucose >7 mmol/L for the duration of the exercise. Six individuals given 10 g of additional carbohydrates, administered \textit{via} a glucose drink. At exercise completion, blood samples were immediately drawn from the cannula.

2.4.1 Flow Cytometry Enumeration of Hematopoietic and Endothelial Progenitor Cells
Angiogenic cells were enumerated by flow cytometer (LSR Fortessa\textsuperscript{™} X20; BD Biosciences, USA) within 4 hours of blood draw. Whole blood collected in EDTA vacutainer (Becton, Dickinson and Company, UK) was incubated with anti-CD34 FITC, anti-VEGFR2 APC, anti-CD45 BV421, anti-CXCR4 APC-Cy7, and anti-CXCR7 PE (BioLegend, USA) in a Trucount\textsuperscript{™} tube (BD Biosciences, USA) with red blood cell lysis buffer (BD PharmLyse\textsuperscript{™}, BD Biosciences, USA). Samples were analysed for 45 minutes or until 500,000 CD45\textsuperscript{+} events had been enumerated.

Flow cytometry files were analysed using FCS Express 7 (De Novo, California, USA). Counts of HPCs (CD34\textsuperscript{+}) and EPCs (CD34\textsuperscript{+}VEGFR2\textsuperscript{+}) and subsequent cell surface expression of chemokine receptor 4 (CXCR4) and 7 (CXCR7) were converted to cells/mL using BD Trucount\textsuperscript{™}, and adjusted for changes in blood volume [further methodology details available elsewhere (31)]. Briefly, these phenotypes were chosen as low circulating CD34\textsuperscript{+} HPCs and CD34\textsuperscript{+}VEGFR2\textsuperscript{+} counts are proven as risk factors to future adverse cardiovascular outcomes and death (25, 27). Surface expression of CXCR4 and CXCR7 gives insight into how these cells respond to a stimuli such as exercise (31), characterising their ability to home to hypoxic environments, and may be a better predictor of mortality than HPCs and EPCs alone (27).

2.5 Statistical Analysis
Analysis was performed using SPSS-24.0 (IBM CORP, Armonk, USA) and GraphPad Prism 8.0.1 (San Diego, USA). Normality and outliers were assessed, with skewed data transformed. A Two-Way Mixed Model ANOVA was used to examine the interaction on cell numbers over time (resting and post exercise) and between groups (Cpepund, Cpephigh and non-diabetes controls), with statically significant effects examined by Bonferroni post-hoc tests. An ANCOVA, adjusting for HbA1c, age or \( \dot{V}O_{2\text{peak}} \) was used to compare all groups across time. An ANCOVA, adjusting for diabetes duration, was used to compare the diabetes groups across time. Data are presented as means ± standard deviation. Statistical significance was set at p≤0.05.

3 RESULTS
Age, BMI and \( \dot{V}O_{2\text{peak}} \) were comparable between all groups (Table 1). The Cpephigh group had significantly shorter duration diabetes (11.4±6.5 years) than Cpepund group (26.2±13.9 years, p=0.006), but similar HbA1c (56±10 vs 61±10 mmol/mol, p=0.486).

Participants exercised at 58% of \( \dot{V}O_{2\text{peak}} \), with no differences between groups (p=0.405). There were no episodes of hypoglycemia (<3.9 mmol/L). Exercise was a significant stressor, inducing a mean energy expenditure of 1558±511 kJ (373±122 kcal), with no differences between groups (p=0.809). There was no missing data.

3.1 Exercise-Induced Change in HPCs and EPCs
There was a significant group*time interaction for HPCs, CXCR4\textsuperscript{+} HPCs and CXCR7\textsuperscript{+} HPCs phenotypes, as well as the CXCR7\textsuperscript{+} EPCs (Figures 1A–C, F). Resting counts were highest for participants without diabetes, lower for Cpephigh group (CXCR4\textsuperscript{+} and CXCR7\textsuperscript{+} HPCs significantly so) and lowest in those with undetectable C-Peptide (all phenotypes significantly
lower than controls, CXXCR7+ EPCs significantly lower than CXXP high). HPCs phenotypes and CXXCR7+ EPCs increased significantly from rest to post-exercise in the CXXP high and non-diabetes control groups (34-121% increase), with no significant changes in the CXXP und group (8-38% increase). For EPCs and CXCR4+ EPCs (Figures 1D, E) no significant group*time existed (p=0.053), however the CXXP und group had significantly lower group counts compared to both the non-diabetes controls and CXXP high groups for these phenotypes (p<0.013).

Results were largely replicated when controlling for HbA1c, age or VO2peak, with only the CXXP high and control groups having significant increases from rest to post-exercise. When controlling for HbA1c, only HPCs lost the significant group*time interaction (p=0.072), despite group counts remaining significantly lower for CXXP und compared to both CXXP high and non-diabetes control groups. Controlling for VO2peak did not alter the significant group*time interactions for any of the phenotypes. When controlling for age, EPCs also had a significant group*time interaction (p=0.034).

When controlling for duration of diabetes between the high and undetectable residual β-cell groups, group*time interactions remained for CXCR4+ HPCs (p=0.014), CXCR7+ HPCs (p=0.030) and CXCR7+ EPCs (p=0.007), but not for HPCs (p=0.060). Additionally, EPCs had a significant group*time interactions (p=0.020). Across all phenotypes, with duration of diabetes controlled at 19 years, CXXP high had exercise-induced increases of 35-131%, whereas CXXP und had no significant increase of between -1 to 9%.

### 4 DISCUSSION

For the first time, we show that a high residual β-cell function in type 1 diabetes is associated with intact exercise-induced increases in circulating HPC and EPC numbers, comparable to non-diabetes controls. However, in those with undetectable C-peptide, rapid mobilisation in response to exercise appears to be lost. This is despite similar HbA1c, age, and fitness between type 1 diabetes groups, all clinical characteristics that previously have been demonstrated to influence circulating counts (22, 26, 36). In combination with research demonstrating that post-islet transplantation patients have improved angiogenic function of EPCs compared to non-transplant controls (37), our data suggest that β-cell function in type 1 diabetes can influence angiogenic cells.

Acute exercise can mobilise EPCs into the circulation in healthy individuals, as well as improving the angiogenic function (38). Exercise-induced increases have been hypothesised as a surrogate marker for mobilisation in response to ischemic stressors. Specifically, reduced exercise-induced mobilisation of CD34+CXCR4+ HPCs is associated with increased CVD in patients with coronary artery disease (27). As the CXXP und group had no significant exercise-induced increases, this may be a mechanism by which this group are at increased risk of future diabetes-related complications (3).

Despite HbA1c being similar between the patient groups at the time of testing, it is possible those with high residual β-cell function have had reduced time spent in hyperglycaemia and improved glycemic variability (3, 10). Additionally, the lack of historic HbA1c determined over the duration of the diabetes is a limitation, as the high β-cell function group may have had reduced exposure to hyperglycaemia over time. Exposing angiogenic cells to hyperglycaemia in vitro results in increased apoptosis and a decrease in function, while improving HbA1c and glycemic variability has been shown increased numbers of circulating cells (22). Hyperglycaemia also leads to increased vascular damage and disruption of bone marrow homeostasis, ultimately resulting in the exhaustion, depletion and inability to mobilise angiogenic cells from within the bone marrow (39).

It is possible that endogenous insulin and C-peptide secretion directly into circulation via the portal vein, may also offer some vasoprotection. In vivo studies demonstrate that insulin improves mobilisation and stimulates the angiogenic function of EPCs (40), while in vitro studies demonstrate C-peptide reduces hyperglycaemia-induced dysfunction in mature vascular endothelial cells (41) and stimulates ATP release from erythrocytes (42). Further investigation is needed to determine
whether the small amounts of endogenous secretion from functioning beta-cells can be protective against diabetes complications.

Even when controlling for duration, circulating counts were higher and exercise-induced increases were only seen in those with high beta-cell function. However, it is important to recognise these results may still be influenced by accumulative years of exposure, with a longer duration of diabetes associated with reduced resting count (36) and our high C-peptide group having a significantly shorter duration. Despite this, some individuals within the high C-peptide group had type 1 diabetes for 20 years. As this was an exploratory study and as such was underpowered, this should be considered as a limitation. However, we hope this novel analysis will inform future studies exploring residual beta-cell function and angiogenic cells, in particular focusing on the development of diabetes complications.

In summary, individuals with type 1 diabetes who have a high residual beta-cell function have an intact ability to increase circulating angiogenic cell numbers in response to exercise. It remains to be determined whether this is due to improved glycaemic control, clinical characteristics or the direct impact of endogenous insulin and C-peptide secretion upon the vasculature. Further investigation is needed to understand if these findings translate to reduced development of micro and macro-vascular complications.

DATA AVAILABILITY STATEMENT
The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.
ETHICS STATEMENT

The studies involving human participants were reviewed and approved by HS HRA North East Tyne & Wear South Research Ethics (code:16/NE/0192) and Newcastle University Ethics Committees. The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

GT recruited participants, designed study, researched data, wrote the manuscript. DW and MR designed study, researched data, wrote the manuscript. JAS recruited participants, designed study, provided clinical cover and reviewed/edited the manuscript. TM analysed samples and reviewed/edited the manuscript, AS processed data, reviewed/edited the manuscript. MC reviewed/edited the manuscript. KS and JHS contributed to data collection and reviewed/editied the manuscript. DW is the guarantor. All authors contributed to the article and approved the submitted version.

REFERENCES

1. Oram RA, McDonald TJ, Shields BM, Hudson MM, Shepherd MH, Hammersley S, et al. Most People With Long-Duration Type 1 Diabetes in a Large Population-Based Study Are Insulin Microsecretors. Diabetes Care (2015) 38(2):323–285. doi: 10.2337/dc14-0871
2. Williams GM, Long AE, Wilson IV, Atkin RJ, Wyatt RC, McDonald TJ, et al. Beta Cell Function and Ongoing Autoimmunity in Long-Standing, Childhood Onset Type 1 Diabetes. Diabetesologia (2016) 59(12):2722–26. doi: 10.1007/s00125-016-4087-0
3. Jeyam A, Colhoun H, McGurnaghan S, Blackbourn L, McDonald TJ, Palmer CNA, et al. Clinical Impact of Residual C-Peptide Secretion in Type 1 Diabetes on Glycaemia and Microvascular Complications. Diabetes Care (2020) 44(2):390–8. doi: 10.2337/doi-20-0567
4. Steffes MW, Sibley S, Jackson M, Thomas W. Beta-Cell Function and the Development of Diabetes-Related Complications in the Diabetes Control and Complications Trial. Diabetes Care (2003) 26(3):832–36. doi: 10.2337/ diacare.26.3.832
5. Lachin JM, McGee P, Palmer JP, Group Dcct Edic Research. Impact of C-Peptide Preservation on Metabolic and Clinical Outcomes in the Diabetes Control and Complications Trial. Diabetes (2014) 63(2):739–485. doi: 10.2337/db13-0881
6. Panero F, Novelli G, Zucco C, Formengo P, Perotto M, Segre O, Fasting Plasma C-Peptide and Micro- and Macrovascular Complications in a Large Clinic-Based Cohort of Type 1 Diabetic Patients. Diabetes Care (2009) 32(2):301–55. doi: 10.2337/dc08-1241
7. KuhlTreiber WM, Wasler SSL, Hsu E, Zhao M, Reinhold P3rd, Burger D, et al. Low Levels of C-Peptide Have Clinical Significance for Established Type 1 Diabetes. Diabetic Med (2015) 32(10):1346–535. doi: 10.1111/ dme.12850
8. Gibb FW, McKnight JA, Clarke C, Strachan MWJ. Preserved C-Peptide Secretion Is Associated With Fewer Low-Glucose Events and Lower Glucose Variability on Flash Glucose Monitoring in Adults With Type 1 Diabetes. Diabetologia (2020) 63(5):906–145. doi: 10.1007/s00125-020-05099-3
9. Rickels MR, Evans-Molina C, Bahnsen HT, Ylensopidez A, Nadeau KJ, Hao W, et al. High Residual C-Peptide Likely Contributes to Glycemic Control in Type 1 Diabetes. J Clin Invest (2020) 130(4):1850–62. doi: 10.1172/JCI134057
10. Taylor GS, Smith K, Capper TE, Scragg JH, Bashir A, Platt A, et al. Postexercise Glycemic Control in Type 1 Diabetes Is Associated With Residual β-Cell Function. Diabetes Care (2020) 43(10):2362–70. doi: 10.2337/dc20-0300
11. Beckman JA, Creager MA. Vascular Complications of Diabetes. Circ Res (2016) 118(11):771–855. doi: 10.1161/CIRCRESAHA.115.306884
12. Buckingham R, Cheng P, Beck RW, Kollman C, Ruedy KJ, Weinzimer SA, et al. CGM-Measured Glucose Values Have a Strong Correlation With C-Peptide, HbA1c and IDAAG, But Do Poorly in Predicting C-Peptide Levels in the Two Years Following Onset of Diabetes. Diabetologia (2015) 58(6):1167–745. doi: 10.1007/s00125-015-3559-y
13. Almeida MH, Dantas JR, Barone B, Serfaty FM, Kuperf R, Albernaz M, et al. Residual C-Peptide in Patients With Type 1 Diabetes and Multiethnic Backgrounds. Clinics (2013) 68(1):123–26. doi: 10.6061/clinics/2013(01)RC02
14. Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, et al. Isolation of Putative Progenitor Endothelial Cells for Angiogenesis. Science (1997) 275(5302):964–67. doi: 10.1126/science.275.5302.964
15. Anantahaseen S, Gudzinaska KN, Bojakowski K, Kurejekamsa E, Geacim O, Soderberg-Nauchl C, et al. Locally Transplanted CD34+ Bone Marrow-Derived Cells Contribute to Vascular Healing After Vascular Injury. Transplant Proc (2017) 49(6). Elsevier. doi: 10.1016/j.transproceed.2017.01.081
16. Leor J, Guetta E, Feinberg MS, Galski H, Bar I, Holbova R, et al. Human Umbilical Cord Blood-Derived CD133+ Cells Enhance Function and Repair of the Infarcted Myocardium. Stem Cells (2006) 24(3):772–805. doi: 10.1634/ stemcells.2005-0212
17. Sidney LE, Branch MJ, Dunphy SE, Dua HS, Hopkinson A. Concise Review: Evidence for CD34 as a Common Marker for Diverse Progenitors. Stem Cells (2014) 32(6):1380–895. doi: 10.1002/stem.1661
18. Van Craenenbroeck EM, Van Craenenbroeck AH, van Ierssel S, Bruyndonckx L, Hoyns VY, Vrints CJ, et al. Quantification of Circulating CD34+/KDR+CD45dim Endothelial Progenitor Cells: Analytical Considerations. Int J Cardiol (2013) 167(5):1688–95. doi: 10.1016/j.ijcard.2012.10.047
19. Sibal L, Aldibbiat A, Agarwal SC, Mitchell G, Oates C, Razvi S, et al. Circulating Endothelial Progenitor Cells, Endothelial Function, Carotid Intima-Media Thickness and Circulating Markers of Endothelial Dysfunction in People With Type 1 Diabetes Without Macrovascular Disease or Microalbuminuria. Diabetologia (2009) 52(8):1464–73. doi: 10.1007/s00125-009-1401-0
20. Palombo C, Kozakova M, Tornacci C, Nesi I, Barossi MC, Spontoni P, et al. Circulating Endothelial Progenitor Cells and Large Artery Structure and Function in Young Subjects With Uncomplicated Type 1 Diabetes. Cardiovasc Diabetol (2011) 10(88). doi: 10.1186/1475-2840-10-88
21. Zahran AM, Mohamed IL, El Asheer OM, Tamer DM, Abo EMGM, Abdel-Rahim MH, et al. Circulating Endothelial Cells, Circulating Endothelial Progenitor Cells, and Circulating Microparticles in Type 1 Diabetes

FUNDING

This study was funded by the Diabetes Research and Wellness Foundation (SCA/OF/12/15) award to DW. Funding was also provided by philanthropic award to DW from the Francis James Bell Endowment Fund, Country Durham Community Foundation. The study funders was not involved in the design of the study; the collection, analysis, and interpretation of data; writing the report; and did not impose any restrictions regarding the publication of the report

ACKNOWLEDGMENTS

The authors thank the study participants for their time, effort, and commitment, as well as the research teams at the Newcastle National Institute for Health Research Clinical Research Facility, Newcastle-upon-Tyne, for their assistance with data collection, and the Newcastle University Flow Cytometry Core Facility (FCCF) for assistance with the generation of Flow Cytometry data.

Frontiers in Endocrinology | www.frontiersin.org 6 February 2022 | Volume 13 | Article 797438
Mellitus. Clin Appl Thromb Hemost (2019) 25:1076029618825311. doi: 10.1177/1076029618825311

22. Hörttihonter, T, Raivialak, T, Satler M, Nagl K, Horsch J, Muller F, et al. Endothelial Progenitor Cells Are Related to Glycemic Control in Children With Type 1 Diabetes Over Time. Diabetes Care (2013) 36(6):1647–53. doi: 10.2337/dc12-1206

23. DiMeglio LA, Tosh A, Saha C, Estes M, Mund J, Mead LE, et al. Endothelial Abnormalities in Adolescents With Type 1 Diabetes: A Biomarker for Vascular Sequelae? J Pediatr (2010) 157(4):540–6. doi: 10.1016/j.jpeds.2010.04.050

24. Loomans CJ, de Koning EJ, Staal FJ, Rookmaaker MB, Verseyden C, de Boer AM. Circulating Progenitor Cells, Cardiovascular Outcomes and Death: A Meta-Analysis of Prospective Observational Studies. Circ Res (2016) 118(12):1930–39. doi: 10.1161/CIRCRESAHA.116.308366

25. Rigato M, Avogaro A, Fadini GP. Levels of Circulating Progenitor Cells, Diabetes Patients Increase CXCR4+ and CXCR7+ Haematopoietic and Endothelial Progenitor Cell Dysfunction: A Novel Concept in the Pathogenesis of Vascular Complications of Type 1 Diabetes. Diabetes (2004) 53(1):195–9. doi: 10.2337/diabetes.53.1.195

26. Hernandez SL, Gong JH, Chen L, Wu IH, Sun JK, Keenan HA, et al. Characterization of Circulating and Endothelial Progenitor Cells in Patients With Extreme-Duration Type 1 Diabetes. Diabetes Care (2014) 37(8):2193–1. doi: 10.2337/dc13-2547

27. Moszitzki K, Lima BR, Hammadah M, Ramadan R, Al Mheid I, Hwan Kim J, et al. Association Between Change in Circulating Progenitor Cells During Exercise Stress and Risk of Adverse Cardiovascular Events in Patients With Coronary Artery Disease. JAMA Cardiol (2020) 5(2):147–55. doi: 10.1001/jamacardio.2019.4212

28. Schier R, El-Zein R, Cortes A, Liu M, Collins M, Rafat N, et al. Endothelial Progenitor Cell Mobilization by Preoperative Exercise: A Bone Marrow Response Associated With Postoperative Outcome. Br J Anaesth (2014) 113(4):652–9. doi: 10.1093/bja/aeu135

29. West DJ, Campbell MD, Gonzalez JT, Walker M, Stevenson EJ, Ahmed FW. The Inflammation, Vascular Repair and Injury Responses to Exercise in Fit Males With and Without Type 1 Diabetes: An Observational Study. Cardiovasc Diabetol (2015) 14(1):715. doi: 10.1186/s12933-015-0235-y

30. Waclawovsky G, Umpierre D, Figueira FR, De Lima ES, Alegretti AP, Schneider L, et al. Exercise on Progenitor Cells in Healthy Subjects and Patients With Type 1 Diabetes. Med Sci Sports Exerc (2015) 48:190–9. doi: 10.1249/MSS.0000000000000764

31. Taylor GS, Shaw A, Smith K, Capper TE, Scruggs JH, Cronin M, et al. Type 1 Diabetes Patients Increase CXCR4+ and CXCR7+ Haematopoietic and Endothelial Progenitor Cells With Exercise, But the Response Is Attenuated. Sci Rep (2021) 11(1):14502. doi: 10.1038/s41598-021-93886-2

32. Sun JK, Keenan HA, Cavallerano JD, Azzalos BS, Schafer EJ, Sell DR, et al. Protection From Retinopathy and Other Complications in Patients With Type 1 Diabetes of Extreme Duration: The Joslin 50-Year Medalist Study. Diabetes Care (2011) 34(4):968–74. doi: 10.2337/dc10-1675

33. Keenan HA, Sun JK, Levine J, Doria A, Aiello LP, Eisenbarth G, et al. Residual Insulin Production and Pancreatic S-Cell Turnover After 50 Years of Diabetes: Joslin Medalist Study. Diabetes (2010) 59(11):2846–53. doi: 10.2337/db10-0676

34. Greenbaum CJ, Mandrup-Poulsen T, McGee PF, Battelino T, Haastert B, Ludvigsson J, et al. Mixed-Meal Tolerance Test Versus Glucagon Stimulation Test for the Assessment of Beta-Cell Function in Therapeutic Trials in Type 1 Diabetes. Diabetes Care (2008) 31(10):1966–71. doi: 10.2337/dc07-2451

35. Bruce RA, Kusumi F, Hosmer D. Maximal Oxygen Intake and Nomographic Assessment of Functional Aerobic Impairment in Cardiovascular Disease. Am Heart J (1973) 85(4):546–62. doi: 10.1016/0002-8703(73)90502-4

36. Arcangeli A, Lastraoli E, Piccini B, D’Amico M, Lenzi L, Pillozzi S, et al. Circulating Endothelial Progenitor Cells in Type 1 Diabetic Patients: Relation With Patients’ Age and Disease Duration. Front Endocrinol (2017) 8(October):278. doi: 10.3389/fendo.2017.00278

37. Petrelli A, Maestroni A, Fadini GP, Belloni D, Venturini M, Albiero M, et al. Improved Function of Circulating Angiogenic Cells Is Evident in Type 1 Diabetic Islet-Transplanted Patients. Am J Transplant (2010) 10(12):2690–700. doi: 10.1038/nke.2010.33309.x

38. Van Craenenbroeck EM, Beckers PJ, Possemiers NM, Wyts K, Frederix G, Hoymans VY, et al. Exercise Acutely Reverses Dysfunction of Circulating Angiogenic Cells in Chronic Heart Failure. Eur Heart J (2010) 31(15):1924–34. doi: 10.1093/eurheartj/ehq038

39. Oikawa A, Siragusa M, Quaini F, Mangialardi G, Kalert RG, Caporali A, et al. Diabetes Mellitus Induces Bone Marrow Microangiopathy. Arterioscler Thromb Vasc Biol (2010) 30(3):498–508. doi: 10.1161/ATVBAHA.109.301154

40. Dong L, Kang L, Ding L, Chen Q, Bai J, Gou R, et al. Insulin Modulates Ischämia-Induced Endothelial Progenitor Cell Mobilization and Neovascularization in Diabetic Mice. Microvasc Res (2011) 82(3):227–36. doi: 10.1016/j.mvr.2011.09.006

41. Bhatt MP, Lee Y-J, Jung S-H, Kim YH, Yun Hwang J, Han E-T. C-Peptide Protects Against Hyperglycemic Memory and Vascular Endothelial Cell Apoptosis. J Endocrinol (2016) 231(1):97–1085. doi: 10.1530/JEO-16-0349

42. Keshavarz H, Meints LM, Geiger MK, Zinn KR, Spence DM. Specific Binding of Leptin to Red Blood Cells Delivers a Pancreatic Hormone and Stimulates Neovascularization in Diabetic Mouse. Mol Pharm (2021) 18(6):2438–75. doi: 10.1021/acs.molpharmaceut.1c00390

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Taylor, Shaw, Scragg, Smith, Campbell, McDonal, Shaw, Ross and West. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.